22 completed, 16 not yet recruiting, 4 recruiting. 42 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 42 | Completed 22, Not yet recruiting 16, Recruiting 4 |
Follow Addpharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults AD-234, AD-2341, AD-2342 - Gastritis | Phase 1 | Not yet recruiting | Addpharma Inc. | 30 | 2026-08-01 | 2026-07-27 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2 | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-29 | 2026-07-28 |
| A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects AD-118, AD-1181 - Chronic Heart Failure | Phase 1 | Not yet recruiting | Addpharma Inc. | 74 | 2026-07-24 | 2026-07-21 |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers AD-116A, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-01 | 2026-07-20 |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers AD-116A, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-01 | 2026-07-27 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C AD-231, AD-231A, AD-231D and AD-231C - Dyslipidemia, Hypertension | Phase 1 | Not yet recruiting | Addpharma Inc. | 60 | 2026-06-01 | 2026-05-15 |
| A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults AD-230, AD-2301 - Chronic Liver Disease (CLD) | Phase 1 | Not yet recruiting | Addpharma Inc. | 52 | 2026-05-01 | 2026-04-13 |
| A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults AD-230 (Fasted), AD-230 (Fed) - Chronic Liver Disease (CLD) | Phase 1 | Not yet recruiting | Addpharma Inc. | 24 | 2026-05-01 | 2026-06-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 AD-123, AD-1231 and AD-1232 - Diabetes Mellitus | Phase 1 | Not yet recruiting | Addpharma Inc. | 50 | 2026-04-01 | 2026-04-20 |
| A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults AD-229, AD-2291 - Gastritis | Phase 1 | Not yet recruiting | Addpharma Inc. | 28 | 2026-04-01 | 2026-02-27 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects AD-118, AD-1181 - Chronic Heart Failure | Phase 1 | Not yet recruiting | Addpharma Inc. | 70 | 2026-04-01 | 2026-03-17 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects AD-116, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Recruiting | Addpharma Inc. | 44 | 2026-02-26 | 2026-03-03 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers AD-117 - Mixed Dyslipidemia, Food Effect Study of AD-117 | Phase 1 | Completed | Addpharma Inc. | 60 | 2026-02-10 | 2026-07-15 |
| Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 Treatment A(AD-2321), Treatment B(AD-2322), Treatment C(AD-2321+AD-2322) - Hypertension | Phase 1 | Not yet recruiting | Addpharma Inc. | 41 | 2026-01-27 | 2025-12-31 |
| Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' AD-115A, AD-1151 - Gastric Ulcer | Phase 1 | Recruiting | Addpharma Inc. | 46 | 2026-01-27 | 2026-02-11 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Treatment A(AD-231A), Treatment B(AD-231B+AD-231C), Treatment C(AD-231A+AD-231B+AD-231C) - Hypertension, Hyperlipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 55 | 2026-01-23 | 2025-12-31 |
| A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers AD-116, AD-1161 - Benign Prostatic Hyperplasia | Phase 1 | Completed | Addpharma Inc. | 44 | 2026-01-22 | 2026-07-28 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A AD-117, AD-117A - Mixed Dyslipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 60 | 2025-12-01 | 2025-12-04 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 AD-228A, AD-2281 and AD-2282 - Primary Hypercholesterolaemia | Phase 1 | Completed | Addpharma Inc. | 60 | 2025-07-12 | 2025-10-01 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B Co-administration of AD-227A and AD-227B, Administration of AD-227 - Primary Hypertension | Phase 1 | Completed | Addpharma Inc. | 70 | 2025-07-12 | 2025-12-01 |
Showing 20 of 42. Sign in to see all of them.
Hyperlipidemias (6) · Hypertension (6) · Gastroesophageal Reflux (5) · Prostatic Hyperplasia (4) · Gastritis (3) · Osteoporosis (2) · Stomach Ulcer (2) · Alopecia (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Embolism and Thrombosis (1) · Essential Hypertension (1) · Pain (1)
Drug Evaluation (4) · Rabeprazole (2) · Raloxifene Hydrochloride (2) · AD 101 (1) · Calcium Carbonate (1) · Cholecalciferol (1) · Esomeprazole (1) · Lansoprazole (1) · Rivaroxaban (1) · Tablets (1)
South Korea (41)
Seunghwan Lee, M.D.,Ph.D (3) · Young-Ran Yoon, M.D., Ph.D (3) · In-Jin Jang, M.D.,Ph.D (2) · HyeWon Chung (1) · In-Jin Jang, M.D., Ph.D (1)